{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:31:14Z","timestamp":1794976274217,"version":"4.9.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol-Myers Squib","id":[{"id":"https:\/\/ror.org\/00gtmwv55","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunoglobulin G4-related disease (IgG4-RD) is a systemic immune-mediated fibroinflammatory disease that is believed but not confirmed to have an autoimmune origin. Since its discovery nearly two decades ago, our understanding of its pathophysiology and clinical manifestations has grown substantially. Early diagnosis and treatment of this elusive disease can prevent substantial organ damage from end-stage fibrosis. This underscores the importance of prompt recognition, full characterization, and astute management. The American College of Rheumatology\/European League Against Rheumatism Classification Criteria provide a framework for approaching the diagnosis of IgG4-RD even though they were not intended for diagnostic purposes. The approach to diagnosis involves recognizing the typical disease manifestations and incorporating clinical, radiological, serological, and histopathological information. The exclusion of disease mimickers, particularly malignancy and other inflammatory conditions, is essential. Both glucocorticoids and B cell depletion are effective at inducing remission in IgG4-RD in most patients. The optimal approach to the use of these agents is now being defined in clinical trials.<\/jats:p>","DOI":"10.1093\/rheumatology\/keaf008","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T23:18:26Z","timestamp":1735859906000},"page":"i24-i27","source":"Crossref","is-referenced-by-count":45,"title":["IgG4-related disease: lessons from the first 20 years"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6588-9435","authenticated-orcid":false,"given":"John H","family":"Stone","sequence":"first","affiliation":[{"name":"Harvard Medical School, Division of Rheumatology, Allergy, and Immunology, The Edward A. Fox Chair in Medicine, Massachusetts General Hospital, Executive Chairman, The IgG4ward! Foundation , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"2025031209170672700_keaf008-B1","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00535-003-1175-y","article-title":"A new clinicopathological entity of IgG4-related autoimmune disease","volume":"38","author":"Kamisawa","year":"2003","journal-title":"J Gastroenterol"},{"key":"2025031209170672700_keaf008-B2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMra1104650","article-title":"IgG4-related disease","volume":"366","author":"Stone","year":"2012","journal-title":"N Engl J Med"},{"key":"2025031209170672700_keaf008-B3","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2665-9913(19)30017-7","article-title":"Management of IgG4-related disease","volume":"1","author":"Zhang","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025031209170672700_keaf008-B4","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2665-9913(24)00022-5","article-title":"Proliferative features of IgG4-related disease","volume":"6","author":"Katz","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2025031209170672700_keaf008-B5","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2665-9913(23)00299-0","article-title":"Fibrotic phenotype of IgG4-related disease","volume":"6","author":"Lanzillotta","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2025031209170672700_keaf008-B6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol"},{"key":"2025031209170672700_keaf008-B7","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jvs.2010.06.072","article-title":"A clinicopathologic study of immunoglobulin G4-related sclerosing disease of the thoracic aorta","volume":"52","author":"Kasashima","year":"2010","journal-title":"J Vasc Surg"},{"key":"2025031209170672700_keaf008-B8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/acr.20095","article-title":"IgG4-related disease accounts for a significant proportion of thoracic lymphoplasmacytic aortitis cases","volume":"62","author":"Stone","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2025031209170672700_keaf008-B9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/BOR.0b013e3283412f7c","article-title":"Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of IgG4-related systemic disease","volume":"23","author":"Stone","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"2025031209170672700_keaf008-B10","doi-asserted-by":"crossref","first-page":"152184","DOI":"10.1016\/j.semarthrit.2023.152184","article-title":"IgG4-related disease as a variable-vessel vasculitis: case series of 13 patients with medium-sized coronary artery involvement","volume":"60","author":"Katz","year":"2023","journal-title":"Seminars Arthritis Rheum"},{"key":"2025031209170672700_keaf008-B11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease","volume":"79","author":"Wallace","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025031209170672700_keaf008-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025031209170672700_keaf008-B13","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1016\/S2665-9913(24)00089-4","article-title":"Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of 328 patients fulfilling the American College of Rheumatology\/European League Against Rheumatism classification criteria","volume":"6","author":"Jha","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2025031209170672700_keaf008-B14","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1093\/rheumatology\/keaa651","article-title":"Differences in clinical characteristics of IgG4-related disease across age groups: a prospective study of 737 patients","volume":"60","author":"Lu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025031209170672700_keaf008-B15","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/rheumatology\/key397","article-title":"Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025031209170672700_keaf008-B16","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/art.39205","article-title":"IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients","volume":"67","author":"Wallace","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025031209170672700_keaf008-B17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2013-204907","article-title":"The diagnostic utility of serum IgG4 concentrations in IgG4-related disease","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025031209170672700_keaf008-B18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ajg.2016.40","article-title":"Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort","volume":"111","author":"Culver","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2025031209170672700_keaf008-B19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025031209170672700_keaf008-B20","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/rheumatology\/kev438","article-title":"Predictors of disease relapse in IgG4-related disease following rituximab","volume":"55","author":"Wallace","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2025031209170672700_keaf008-B21","first-page":"186","article-title":"Risk factors of relapse following glucocorticoid tapering in IgG4-related disease","volume":"36(Suppl 112)","author":"Sasaki","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025031209170672700_keaf008-B22","first-page":"408","article-title":"The positive predictive value of a very high serum IgG4 concentration for the diagnosis of IgG4-related disease","volume":"50","author":"Baker","year":"2023","journal-title":"J Rheumatol"},{"key":"2025031209170672700_keaf008-B23","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.27435","article-title":"Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease","volume":"62","author":"Khosroshahi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025031209170672700_keaf008-B24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MD.0b013e3182431ef6","article-title":"Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients","volume":"91","author":"Khosroshahi","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"2025031209170672700_keaf008-B25","doi-asserted-by":"crossref","first-page":"e0183844","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients","volume":"12","author":"Ebbo","year":"2017","journal-title":"PLoS One"},{"key":"2025031209170672700_keaf008-B26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejim.2019.12.029","article-title":"Long-term efficacy of maintenance therapy with rituximab for IgG4-related disease","volume":"74","author":"Campochiaro","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2025031209170672700_keaf008-B27","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s41927-020-00140-9","article-title":"Use of rituximab in idiopathic retroperitoneal fibrosis","volume":"4","author":"Boyeva","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2025031209170672700_keaf008-B28","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of IgG4-related disease","author":"Stone","year":"2024","journal-title":"N Engl J Med"},{"key":"2025031209170672700_keaf008-B29","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1016\/S2665-9913(23)00157-1","article-title":"Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial","volume":"5","author":"Perugino","year":"2023","journal-title":"Lancet Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/Supplement_1\/i24\/62374848\/keaf008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/Supplement_1\/i24\/62374848\/keaf008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T05:17:54Z","timestamp":1741756674000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/Supplement_1\/i24\/8069375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":29,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,3,12]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf008","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3,1]]}}}